The approval clears the way for clinicians to utilize the SUPERA stent for patients with peripheral vascular disease (PVD) as well as those diagnosed with biliary strictures resulting from malignant neoplasms.
IDEV president and CEO Christopher Owens said with the full regulatory approval that has been granted they can immediately launch SUPERA VERITAS throughout Canada.
"Based on early work with key physicians we anticipate rapid acceptance of our technology, and are pleased to offer this treatment option to physicians and their patients," Owens said.
